CA-AQUA-SPHERE
Aqua Sphere , the premier swimming and triathlon equipment brand, today announced World Champion triathlete Mirinda “Rinny” Carfrae is joining the team as a global brand ambassador. As part of the Aqua Sphere team of athletes, Carfrae will train and compete utilizing the industry-leading Aqua Sphere range of products from training equipment to performance swimsuits and goggles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200825005255/en/
Carfrae, a three-time Ironman World Champion, will help grow the brand globally alongside her husband and fellow World Champion triathlete, Timothy O’Donnell. Carfrae and O’Donnell are part of Aqua Sphere’s growing roster of elite athletes that also includes World Champion Terenzo Bozzone, among others.
“I’m thrilled to be joining the Aqua Sphere team alongside my husband, Tim. I appreciate the long-term brand vision and I’m confident that Tim and I can make an immediate impact, especially as we embark on product designs heading into 2021,” said Carfrae. “Aqua Sphere has a significant global reach and their wide range of categories fit all our training and racing needs. The goggles fit great and have perfect clarity and I can’t wait to race in the gear once we start competitions again. Everyone we have worked with at Aqua Sphere shares an amazing passion for the brand and has welcomed us like family. And yes, the kid’s goggles are also Izzy approved.”
As a leader in the development of new and innovative swim products for athletes of all ages and abilities, Aqua Sphere has tapped Carfrae to endorse its entire product portfolio, including eye protection, swimwear, triathlon wetsuits and speedsuits, and swim fitness and training accessories. She will also contribute her unique perspective and insight to future product innovations.
“Rinny is a world class athlete who is dedicated to her sport and her family, and we are fortunate to have her join our team at Aqua Sphere,” said Andrew Gritzbaugh, General Manager of Aqua Lung, the parent company of Aqua Sphere. “As one of the world’s most decorated female triathletes, her experience, insights and talent are welcomed assets to the Aqua Sphere brand as we continue to solidify our category leadership position in the triathlon space.”
Originally from Australia, and now residing in Boulder, Colo., Carfrae is one of the world’s most successful triathletes. She has won three Ironman World Championships in 2010, 2013, and 2014 and her run course record from 2014 still stands today (2:50:26). With over 50 wins at major events throughout the world and seven podium performances at Kona in the span of a decade, Carfrae is recognized as one the of the greatest triathletes of all time.
Carfrae is currently gearing up to compete at Ironman World Championships – Kona in 2021.
About AQUA SPHERE
Established in Genoa, Italy, in 1998, Aqua Sphere is the premier swimming and triathlon equipment brand. With the launch of its cutting-edge Seal Mask—the world’s first swim mask, the company set the industry standard and today continues to innovate with a complete range of premium products, including eye protection, swimwear, triathlon wetsuits, speedsuits, swim fitness and training accessories. The designs have gained the respect and loyal following of many celebrities and notable athletes, including the world’s most decorated Olympian Michael Phelps, with whom Aqua Sphere has launched Phelps, a global brand of performance swimwear. Alongside its parent company Aqua Lung and supported by an international distribution network, Aqua Sphere has grown into a worldwide enterprise representing unparalleled design, development and manufacturing expertise, with a global footprint in more than 60 countries. For more information, visit: www.AquaSphereSwim.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005255/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom